Study to evaluate the abuse potential of AZD7325 in healthy recreational central nervous system (CNS) depressant users
Study identifier:D1140C00008
ClinicalTrials.gov identifier:N/A
EudraCT identifier:N/A
CTIS identifier:N/A
Study Complete
Official Title
A Single-Centre, Single-Dose, Double-Blind, Randomized, Placebo- and Active-Controlled Crossover Study to Evaluate the AbusePotential of AZD7325 in Healthy Recreational CNS Depressant Users
Medical condition
Recreational CNS Depressant Use
Phase
Phase 1
Healthy volunteers
No
Study drug
Lorazepam, AZD7325, Placebo
Sex
All
Actual Enrollment
100
Study type
Interventional
Age
18 Years - 55 Years
Date
Study Start Date: 01 May 2009
Primary Completion Date: -
Study Completion Date: 01 Sept 2009
Study design
Allocation: Randomized
Endpoint Classification: N/A
Intervention Model: Crossover Assignment
Masking: Double Blind
Primary Purpose: Other
Verification:
Verified 01 Nov 2013 by AstraZeneca
Sponsors
AstraZeneca
Collaborators
-
Inclusion and exclusion criteria
Loading...
No locations available
| Arms | Assigned Interventions |
|---|---|
| Placebo Comparator: A Placebo | - |
| Active Comparator: B Lorazepam | Drug: Lorazepam mg, oral dose |
| Active Comparator: C Lorazepam | Drug: Lorazepam mg, oral dose |
| Active Comparator: D Lorazepam | Drug: Lorazepam mg, oral dose |
| Experimental: E AZD7325 | Drug: AZD7325 mg, oral dose |
| Experimental: F AZD7325 | Drug: AZD7325 mg, oral dose |
| Experimental: G AZD7325 | Drug: AZD7325 mg, oral dose |
Contacts
Investigators
Principal Investigator
Myroslava K Romach
Kendle Early Stage - Toronto
